This substantiates what has been going on in the background:-
Most important in the eyes of the FDA and the industry. Broad application and combination therapies are pretty much the goal in achieving the best outcomes for cancer patients now.
Ann: PTX-100 clinical data presented at leading TCL meeting, page-7
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
4.4¢ |
Change
-0.002(4.35%) |
Mkt cap ! $35.43M | |||
| Open | High | Low | Value | Volume |
| 4.6¢ | 4.6¢ | 4.4¢ | $30.02K | 663.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 691726 | 4.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 4.7¢ | 632704 | 2 |
View Market Depth
| Last trade - 16.10pm 25/06/2025 (20 minute delay) ? |
| PTX (ASX) Chart |